

NEWS RELEASE

**Sunstone makes a non-revocable commitment to sell all shares in Nuevolution at a price of SEK 32.5 per share to Amgen, corresponding to SEK 332 million.**

**Copenhagen, 22 May 2019** – Sunstone today announced that its Life Science Ventures Fund I has made a non-revocable commitment to sell all shares in Nuevolution AB at a price of SEK 32.5 per share.

Nuevolution has been part of Sunstone's portfolio since 2007 and Sunstone has played an active role in developing the company to a stage that has motivated Amgen to make a bid for it. Sunstone is the biggest shareholder (20.7 %) and has participated in all financings and has been represented on Nuevolution's board of directors for more than 10 years. During this period Nuevolution has matured from an intriguing startup to a novel discovery platform company, now impacting how small molecules drugs are being developed in the pharmaceutical industry.

Many partners have over the years benefitted from the technology by way of partnerships and licenses and have in return enabled Nuevolution to build a world leading expertise in small molecules drug discovery. In Sunstone's view the interest from Amgen is a strong testament to the level of maturity, which the technology has achieved as well as to the dedicated expertise available only at Nuevolution.

Considering Nuevolution's current share price, the stage of development and the close to 3 times multiple on the latest share price, Sunstone has concluded that the offer made by Amgen reflects an attractive return to Sunstone and has accordingly made a non-revocable agreement to sell all shares.

Commenting on the announcement, Søren Lemonius, Managing General Partner, said: "Sunstone believes that Amgen's focus on innovation and long entrepreneurial history can provide an inspiring and productive new home for the team at Nuevolution".

**About Nuevolution AB (publ)**

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution's internal programs are focused on therapeutically important disease targets within severe inflammatory diseases and cancer.

**About Sunstone Life Science Ventures:**

Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone

Life Science Ventures has invested in more than 40 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. Managing total funds of approx. €500 million, Sunstone Life Science Ventures is one of the largest European venture capital investors.

**Sunstone contact:** Søren Lemonius  
Managing General Partner  
+45 40 81 48 89  
[lemonius@sunstone.eu](mailto:lemonius@sunstone.eu)